Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D2 receptor agonists

Journal of Medicinal Chemistry

Volumn 55, Issue 16, 2012, Pages 7141-7153

  Chen, Xin ^a   Sassano, Maria F ^b   Zheng, Lianyou ^a,c   Setola, Vincent ^b   Chen, Meng ^d   Bai, Xu ^c   Frye, Stephen V ^a   Wetsel, William C ^d   Roth, Bryan L ^b   Jin, Jian ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c JILIN UNIVERSITY   (China)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [4 [4 (2,3 DICHLOROPHENYL)PIPERIDIN 1 YL]BUTOXY]BENZO[D]THIAZOLE; ARIPIPRAZOLE; BETA ARRESTIN; CYCLIC AMP; DOPAMINE 2 RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; LIGAND; UNC 9975; UNC 9994; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; STRUCTURE FUNCTIONAL SELECTIVITY RELATIONSHIP;

ANIMALS; ANTIPSYCHOTIC AGENTS; ARRESTINS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; FEMALE; HEK293 CELLS; HUMANS; HYPERKINESIS; LIGANDS; MALE; MICE; MICE, KNOCKOUT; PHENCYCLIDINE; PIPERAZINES; QUINOLONES; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866934645     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300603y     Document Type: Article

References (46)

1. Furchgott, R. F. The use of haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of agonist-receptor complexes. In Advances in Drug Research; Harper, N.; Simmonds, A., Eds.; Academic Press: New York, 1966; Vol. 3, pp 21-55.
2. Roth, B. L.; Chuang, D. M. Multiple mechanisms of serotonergic signal transduction. Life Sci. 1987, 41, 1051-1064.
3. Berg, K. A.; Maayani, S.; Goldfarb, J.; Scaramellini, C.; Leff, P.; Clarke, W. P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 1998, 54, 94-104.
4. Parrish, J.; Braden, M.; Gundy, E.; Nichols, D. E. Differential phospholipase C activation by phenylalkylamine serotonin 5-HT2A receptor agonists. J. Neurochem. 2005, 95, 1575-1584.
5. Ghosh, D.; Snyder, S. E.; Watts, V. J.; Mailman, R. B.; Nichols, D. E. 9-Dihydroxy-2, 3, 7, 11b-tetrahydro-1H-naph[1, 2, 3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid beta-phenyldop-amine pharmacophore. J. Med. Chem. 1996, 39, 549-555.
6. Kilts, J. D.; Connery, H. S.; Arrington, E. G.; Lewis, M. M.; Lawler, C. P.; Oxford, G. S.; O'Malley, K. L.; Todd, R. D.; Blake, B. L.; Nichols, D. E.; Mailman, R. B. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J. Pharmacol. Exp. Ther. 2002, 301, 1179-1189.
7. Mottola, D. M.; Kilts, J. D.; Lewis, M. M.; Connery, H. S.; Walker, Q. D.; Jones, S. R.; Booth, R. G.; Hyslop, D. K.; Piercey, M.; Wightman, R. M.; Lawler, C. P.; Nichols, D. E.; Mailman, R. B. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J. Pharmacol. Exp. Ther. 2002, 301, 1166-1178.
8. Beaulieu, J. M.; Tirotta, E.; Sotnikova, T. D.; Masri, B.; Salahpour, A.; Gainetdinov, R. R.; Borrelli, E.; Caron, M. G. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J. Neurosci. 2007, 27, 881-885.
9. Beaulieu, J. M.; Sotnikova, T. D.; Marion, S.; Lefkowitz, R. J.; Gainetdinov, R. R.; Caron, M. G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122, 261-273.
10. Chidiac, P.; Hebert, T.; Valiquette, M.; Dennis, M.; Bouvier, M. Inverse agonist activity of beta-adrenergic antagonists. Mol. Pharmacol. 1993, 45, 490-499.
11. Barker, E. L.; Westphal, R. S.; Schmidt, D.; Sanders-Bush, E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem. 1994, 269, 11687-11690.
12. Rauser, L.; Savage, J. E.; Meltzer, H. Y.; Roth, B. L. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J. Pharmacol. Exp. Ther. 2001, 299, 83-89.
13. Gilliland, S. L.; Alper, R. H. Characterization of dopaminergic compounds at hD2short, hD4.2 and hD4.7 receptors in agonist-stimulated [35S]GTPgammaS binding assays. Naunyn Schmiedebergs Arch. Pharmacol. 2000, 361, 498-504.
14. Burstein, E. S.; Ma, J.; Wong, S.; Gao, Y.; Pham, E.; Knapp, A. E.; Nash, N. R.; Olsson, R.; Davis, R. E.; Hacksell, U.; Weiner, D. M.; Brann, M. R. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther. 2005, 315, 1278-1287.
15. Peroutka, S. J.; Snyder, S. H. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 1980, 210, 88-90.
16. Berry, S.; Shah, M.; Khan, N.; Roth, B. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Mol. Pharmacol. 1996, 50, 306-313.
17. Willins, D. L.; Alsayegh, L.; Berry, S. A.; Backstrom, J. R.; Sanders-Bush, E.; Friedman, L.; Khan, N.; Roth, B. L. Serotonergic antagonist effects on trafficking of serotonin 5-HT2A receptors in vitro and in vivo. Ann. N.Y. Acad. Sci. 1998, 861, 121-127.
18. Willins, D.; Berry, S.; Alsayegh, L.; Backstrom, J.; Sanders-Bush, E.; Roth, B. Clozapine and other 5-hydroxytryptamine2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine2A receptors in vitro and in vivo. Neuroscience 1999, 91, 599-606.
19. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007, 320, 1-13.
20. Mailman, R. B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol. Sci. 2007, 28, 390-396.
21. Luttrell, L. M.; Ferguson, S. S.; Daaka, Y.; Miller, W. E.; Maudsley, S.; Della Rocca, G. J.; Lin, F.; Kawakatsu, H.; Owada, K.; Luttrell, D. K.; Caron, M. G.; Lefkowitz, R. J. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999, 283, 655-661.
22. Lefkowitz, R. J.; Shenoy, S. K. Transduction of receptor signals by beta-arrestins. Science 2005, 308, 512-517.
23. Abbas, A.; Roth, B. L. Arresting serotonin. Proc. Natl. Acad. Sci. U.S.A 2008, 105, 831-832.
24. Urban, J. D.; Vargas, G. A.; von Zastrow, M.; Mailman, R. B. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007, 32, 67-77.
25. Violin, J. D.; Lefkowitz, R. J. [beta]-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 2007, 28, 416-422.
26. Gesty-Palmer, D.; Flannery, P.; Yuan, L.; Corsino, L.; Spurney, R.; Lefkowitz, R. J.; Luttrell, L. M. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci. Transl. Med. 2009, 1, 1ra1.
27. Butini, S.; Gemma, S.; Campiani, G.; Franceschini, S.; Trotta, F.; Borriello, M.; Ceres, N.; Ros, S.; Coccone, S. S.; Bernetti, M.; De Angelis, M.; Brindisi, M.; Nacci, V.; Fiorini, I.; Novellino, E.; Cagnotto, A.; Mennini, T.; Sandager-Nielsen, K.; Andreasen, J. T.; Scheel-Kruger, J.; Mikkelsen, J. D.; Fattorusso, C. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. J. Med. Chem. 2009, 52, 151-169.
28. Allen, J. A.; Yost, J. M.; Setola, V.; Chen, X.; Sassano, M. F.; Chen, M.; Peterson, S.; Yadav, P. N.; Huang, X.-P.; Feng, B.; Jensen, N. H.; Che, X.; Bai, X.; Frye, S. V.; Wetsel, W. C.; Caron, M. G.; Javitch, J. A.; Roth, B. L.; Jin, J. Discovery of Beta-Arrestin-Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 18488-18493.
29. Lawler, C. P.; Prioleau, C.; Lewis, M. M.; Mak, C.; Jiang, D.; Schetz, J. A.; Gonzalez, A. M.; Sibley, D. R.; Mailman, R. B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999, 20, 612-627.
30. Mailman, R. B.; Murthy, V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr. Pharm. Des. 2010, 16, 488-501.
31. Mallikaarjun, S.; Salazar, D. E.; Bramer, S. L. Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers. J. Clin. Pharmacol. 2004, 44, 179-187.
32. Johnson, D. S.; Choi, C.; Fay, L. K.; Favor, D. A.; Repine, J. T.; White, A. D.; Akunne, H. C.; Fitzgerald, L.; Nicholls, K.; Snyder, B. J.; Whetzel, S. Z.; Zhang, L.; Serpa, K. A. Discovery of PF-00217830: Aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder. Bioorg. Med. Chem. Lett. 2011, 21, 2621-2625.
33. Oshiro, Y.; Sato, S.; Kurahashi, N.; Tanaka, T.; Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Nishi, T. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl) butoxy]-3, 4-dihydro-2(1H)-qui-nolinone derivatives. J. Med. Chem. 1998, 41, 658-667.
34. Vangveravong, S.; Zhang, Z.; Taylor, M.; Bearden, M.; Xu, J.; Cui, J.; Wang, W.; Luedtke, R. R.; Mach, R. H. Synthesis and characterization of selective dopamine D(2) receptor ligands using aripiprazole as the lead compound. Bioorg. Med. Chem. 2011, 19, 3502-3511.
35. Martin, G. E.; Elgin, R. J.; Mathiasen, J. R.; Davis, C. B.; Kesslick, J. M.; Baldy, W. J.; Shank, R. P.; Distefano, D. L.; Fedde, C. L.; Scott, M. K. Activity of Aromatic Substituted Phenylpiperazines Lacking Affinity for Dopamine Binding Sites in a Preclinical Test of Antipsychotic Efficacy. J. Med. Chem. 1989, 32, 1052-1056.
36. Elworthy, T. R.; Ford, A. P. D. W.; Bantle, G. W.; Morgans, D. J.; Ozer, R. S.; Palmer, W. S.; Repke, D. B.; Romero, M.; Sandoval, L.; Sjogren, E. B.; Talamas, F. X.; Vazquez, A.; Wu, H.; Arredondo, N. F.; Blue, D. R.; DeSousa, A.; Gross, L. M.; Kava, M. S.; Lesnick, J. D.; Vimont, R. L.; Williams, T. J.; Zhu, Q. M.; Pfister, J. R.; Clarke, D. E. N-Arylpiperazinyl-N′-propylamino derivatives of heteroaryl amides as functional uroselective alpha(1)- adrenoceptor antagonists. J. Med. Chem. 1997, 40, 2674-2687.
37. Fu, X. T.; Lei; Yuan, M.; Shi, J. Design, synthesis and vasorelaxant activity of R, S-1-(substituted phenyl)-4-[3-(naphtha-1-yl-oxy)-2-hydroxypropyl] -piperazine derivatives. Yaoxue Xuebao 2007, 42, 735-740.
38. Tsuruta, K.; Frey, E. A.; Grewe, C. W.; Cote, T. E.; Eskay, R. L.; Kebabian, J. W. Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 1981, 292, 463-465.
39. Banno, K.; Fujioka, T.; Kikuchi, T.; Oshiro, Y.; Hiyama, T.; Nakagawa, K. Studies on 2(1H)-quinolinone derivatives as neuroleptic agents I. Synthesis and biological activities of (4-phenyl-1-piperazinyl)-propoxy-2(1H)-quinolinone derivatives. Chem. Pharm. Bull. 1988, 36, 4377-4388.
40. Kiss, B.; Horvath, A.; Nemethy, Z.; Schmidt, E.; Laszlovszky, I.; Bugovics, G.; Fazekas, K.; Hornok, K.; Orosz, S.; Gyertyan, I.; Agai-Csongor, E.; Domany, G.; Tihanyi, K.; Adham, N.; Szombathelyi, Z. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 2010, 333, 328-340.
41. van Wijngaarden, I.; Kruse, C. G.; van der Heyden, J. A.; Tulp, M. T. 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 2. J. Med. Chem. 1988, 31, 1934-1940.
42. van Wijngaarden, I.; Kruse, C. G.; van Hes, R.; van der Heyden, J. A.; Tulp, M. T. 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J. Med. Chem. 1987, 30, 2099-2104.
43. Bohn, L. M.; Lefkowitz, R. J.; Gainetdinov, R. R.; Peppel, K.; Caron, M. G.; Lin, F. T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286, 2495-2498.
44. Nordquist, R. E.; Risterucci, C.; Moreau, J. L.; von Kienlin, M.; Kunnecke, B.; Maco, M.; Freichel, C.; Riemer, C.; Spooren, W. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 2008, 54, 405-416.
45. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR chemical shifts of common laboratory solvents as trace impurities. J. Org. Chem. 1997, 62, 7512-7515.
46. Barnea, G.; Strapps, W.; Herrada, G.; Berman, Y.; Ong, J.; Kloss, B.; Axel, R.; Lee, K. J. The genetic design of signaling cascades to record receptor activation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 64-69.